Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06980922) titled 'The Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension' on May 19.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chang Gung Memorial Hospital
Condition:
Intradialytic Hypotension
End-Stage Renal Disease
Hemodialysis
Intervention:
Drug: Guilu Erxian Jiao
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 1, 2025
Target Sample Size: 34
Countries of Recruitment:
Taiwan
To know more, visit https://clinicaltria...